M
Mary-Anne Trabaud
Researcher at University of Lyon
Publications - 28
Citations - 623
Mary-Anne Trabaud is an academic researcher from University of Lyon. The author has contributed to research in topics: Viral load & Integrase. The author has an hindex of 12, co-authored 27 publications receiving 533 citations. Previous affiliations of Mary-Anne Trabaud include HCL Technologies.
Papers
More filters
Journal ArticleDOI
Hepatitis E virus mutations associated with ribavirin treatment failure result in altered viral fitness and ribavirin sensitivity
Yannick Debing,Christophe Ramière,Kai Dallmeier,Géraldine Piorkowski,Mary-Anne Trabaud,Fanny Lebossé,Caroline Scholtes,Magali Roche,Catherine Legras-Lachuer,Xavier de Lamballerie,Patrice Andre,Johan Neyts +11 more
TL;DR: A patient with chronic hepatitis E experiencing ribavirin treatment failure with a completely resistant phenotype is presented and viral mutations associated with treatment failure are identified and investigated to investigate the underlying causes of treatment failure.
Journal ArticleDOI
Evaluation of the Genotypic Prediction of HIV-1 Coreceptor Use versus a Phenotypic Assay and Correlation with the Virological Response to Maraviroc: the ANRS GenoTropism Study
Patricia Recordon-Pinson,Cathia Soulié,Philippe Flandre,Diane Descamps,Mouna Lazrek,Charlotte Charpentier,Brigitte Montes,Mary-Anne Trabaud,Jacqueline Cottalorda,Véronique Schneider,Laurence Morand-Joubert,Catherine Tamalet,Delphine Desbois,Muriel Macé,Virginie Ferré,Astrid Vabret,Annick Ruffault,Coralie Pallier,Stéphanie Raymond,Jacques Izopet,Jacques Reynes,Anne-Geneviève Marcelin,Bernard Masquelier +22 more
TL;DR: There were strong arguments in favor of using genotypic coreceptor use assays for determining which patients would respond to CCR5 antagonist.
Journal ArticleDOI
Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France
Diane Descamps,Marie-Laure Chaix,Brigitte Montes,Sophie Pakianather,Charlotte Charpentier,Alexandre Storto,Francis Barin,Georges Dos Santos,Anne Krivine,Constance Delaugerre,Jacques Izopet,Anne-Geneviève Marcelin,Anne Maillard,Laurence Morand-Joubert,Coralie Pallier,Jean-Christophe Plantier,Catherine Tamalet,Jacqueline Cottalorda,Delphine Desbois,Vincent Calvez,Françoise Brun-Vézinet,Bernard Masquelier,Dominique Costagliola,Chakib Alloui,D. Bettinger,G. Anies,B. Masquelier,S. Vallet,Cécile Henquell,M. Bouvier-Alias,G. DosSantos,Anne Signori-Schmuck,S. Rogez,Patrice Andre,Jean-Claude Tardy,Mary-Anne Trabaud,C. Tamalet,B. Montes,J. Cottalorda,Diane Descamps,F. Brun-Vézinet,C. Charpentier,Marie Laure Chaix,D. Desbois,Slim Fourati,A. G. Marcelin,V. Calvez,Philippe Flandre,L. Morand-Joubert,C. Delaugerre,Annick Ruffault,A. Maillard,J. C. Plantier,Thomas Bourlet,Henia Saoudin,J. Izopet,F. Barin +56 more
TL;DR: In France in 2006/2007, the prevalence of transmitted drug-resistant variants was 10.6%, comparable in B and non-B subtypes and prevalence of non- B subtypes is still rising.
Journal ArticleDOI
HIV-1 Load Comparison Using Four Commercial Real-Time Assays
Thomas Bourlet,Anne Signori-Schmuck,Laurent Roche,Vinca Icard,Henia Saoudin,Mary-Anne Trabaud,Jean-Claude Tardy,Patrice Morand,Bruno Pozzetto,René Ecochard,Patrice Andre +10 more
TL;DR: A risk of viral load misestimating or discrepancies between techniques, depending on the HIV-1 subtype, is indicated and speaking in favor of using the same assay for the monitoring of HIV- 1-infected patients is spoken in favor.
Journal ArticleDOI
Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients
Slim Fourati,Charlotte Charpentier,Corinne Amiel,Laurence Morand-Joubert,Sandrine Reigadas,Mary-Anne Trabaud,Constance Delaugerre,Florence Nicot,Audrey Rodallec,Anne Maillard,Audrey Mirand,Hélène Jeulin,Brigitte Montes,Francis Barin,Dominique Bettinger,Hélène Le Guillou-Guillemette,Sophie Vallet,Anne Signori-Schmuck,Diane Descamps,Vincent Calvez,Philippe Flandre,Anne-Geneviève Marcelin +21 more
TL;DR: This study shows that a high proportion of viruses remain susceptible to doluteg Gravir in the case of failure on a raltegravir-containing regimen.